ProCE Banner Activity

NF1-Associated Tumors and MEK Inhibitors: Answers to Your Questions

Clinical Thought

Gain expert insights on key clinically relevant questions related to the care of patients with NF1-associated tumors including the use of MRI scans vs biopsies for diagnosis, use of MEK inhibitor therapy in adults, and managing rashes associated with MEK inhibitors.

Released: January 24, 2025

Expiration: January 23, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Alexion Pharmaceuticals and SpringWorks Therapeutics, Inc.

Alexion Pharmaceuticals

SpringWorks Therapeutics, Inc.

Disclosure

Primary Author

Jaishri Blakeley, MD

The Marjorie Bloomberg Tiven Professor of Neurofibromatosis
Director, The Neurofibromatosis Therapeutic Acceleration Program
Director, the Johns Hopkins Comprehensive Neurofibromatosis Program
Professor of Neurology, Neurosurgery and Oncology
The Johns Hopkins School of Medicine
Baltimore, Maryland

Jaishri Blakeley, MD: consultant/advisor/speaker: Alexion, SpringWorks; researcher: Bristol Myers Squibb.

Miriam Bornhorst, MD

Neuro-Oncologist
Max Lacewell Endowed Brain Tumor Research Scholar
NF-Oncology
Ann & Robert H. Lurie Children’s Hospital
Stanley Manne Children’s Research Institute
Associate Professor of Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Miriam Bornhorst, MD: consultant/advisor/speaker: Alexion.

Michael J. Fisher, MD

Chief, Neuro-Oncology Section
Director, Neurofibromatosis Program
Hubert J.P. and Anne Faulkner Schoemaker Endowed Chair in Pediatric Neuro-Oncology
Center for Childhood Cancer Research and Division of Oncology
The Children’s Hospital of Philadelphia
Professor of Pediatrics
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania

Michael J. Fisher, MD: consultant/advisor/speaker: AstraZeneca, Day One, SpringWorks; researcher: Array BioPharma, AstraZeneca, Exelixis.